Trajectory-based profiling of 52-week secukinumab response reveals baseline clinical and transcriptomic differences in plaque psoriasis
BackgroundResponse to secukinumab in psoriasis varies over time and is not fully captured by single timepoint endpoints. Baseline features associated with long-term response trajectories remain unclear.ObjectiveTo identify 52-week secukinumab response …